The Use of Cannabis (Marijuana) and Cannabidiol (CBD) Among Cancer Patients: A Pilot Study

April 13, 2026 updated by: M.D. Anderson Cancer Center
To collect information about how patients in the pain management clinic use cannabis/CBD, including how often it is used, why it is used (for example, to manage pain or other symptoms), and where patients get their information on cannabis/CBD for pain management

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Objectives

Primary Objective:

The primary objective of this study is to investigate the prevalence of current and prior cannabis and/or CBD use in cancer patients who present to the pain management clinic at MDACC.

Secondary Objectives:

The secondary objective is to investigate the reason for cannabis/CBD use (e.g. pain, neuropsychiatric symptoms, recreational or other use), degree of symptom improvement with use, frequency of use, methods of use (e.g. inhaled vs. ingested), sources of information on cannabis/CBD, and patient interest in learning more from their physicians about cannabis/CBD for cancer pain.

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Texas
      • Houston, Texas, United States, 77030
        • M D Anderson Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

M D Anderson Cancer Center

Description

Inclusion Criteria:

  1. Age 18 years or older
  2. Cancer patients who present to the MD Anderson Pain Medicine Clinic as a new patient or consult
  3. Willing to give informed consent
  4. Willing to complete the survey

Exclusion Criteria:

  1. Refusal of informed consent
  2. Refusal to complete the survey
  3. Patients who previously completed the survey
  4. Patients who opt-out or change their mind after agreeing to participate
  5. Already an established patient at MDACC Pain Medicine Clinic
  6. Patients scheduled to see Dr Abdi (PI).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Cannabis (Marijuana) and Cannabidiol (CBD)
This is a survey to determine the number of cancer pain patients who use and/or used Marijuana and/or CBD for pain or other symptom burdens.
Behavioral: Cannabis (Marijuana)
The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education.
Behavioral: Cannabidiol (CBD)
The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cannabis (Marijuana) and CBD (Cannabidiol for Cancer Pain Survey
Time Frame: through study completion; an average of 1 year.
Score scale ranges from 1-5, Extremely interested(1),Not Interested (5)
through study completion; an average of 1 year.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

M.D. Anderson Cancer Center

Investigators

  • Principal Investigator: Salahadin Abdi, MD,PHD, M.D. Anderson Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 30, 2023

Primary Completion (Estimated)

May 31, 2027

Study Completion (Estimated)

May 31, 2027

Study Registration Dates

First Submitted

April 19, 2023

First Submitted That Met QC Criteria

April 20, 2023

First Posted (Actual)

May 1, 2023

Study Record Updates

Last Update Posted (Actual)

April 16, 2026

Last Update Submitted That Met QC Criteria

April 13, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2022-0049
  • NCI-2023-03440 (Other Identifier: NCI-CTRP Clinical Trials Registry)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Clinical Trials on Cannabis (Marijuana)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe